Form 4 for MBX MBX Biosciences, Inc.
Accepted 2026-02-27 00:00:00 ET · period of report 2026-02-26 · accession 0001193125-26-082562 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-27 | 2026-02-26 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $16.00 | +28.8K | 728.3K | +4% | +$460.3K |
| D | 2026-02-27 | 2026-02-26 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $0.00 | -28.8K | 91.7K | -24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-26 | M | A | 28,768 | $16.00 | 728,274 | D | — | — | |
| 2 | Derivative | Stock option (right to buy) | 2026-02-26 | M | D | 28,768 | $0.00 | 91,668 | D | $16.00 · — to 2034-09-12 | 28,768 Common Stock | (F2) 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |